June 14, 2010
Gilead Sciences recently announced an extension of discounts and price freezes for several HIV drugs used by clients of AIDS drug assistance programs. Many state ADAPs continue to face budget shortfalls, and as of May there were 1,143 individuals on waiting lists for ADAP assistance, the drug maker noted in a statement issued jointly with the ADAP Crisis Task Force. Discounts and price freezes cover Truvada (emtricitabine and tenofovir), Viread (tenofovir), and Emtriva (emtricitabine) through December 31, 2013. In addition, Gilead said it is expanding its patient assistance program and eliminating minimum payments for patients in its co-pay assistance program. The ADAP Crisis Task Force was formed in 2002 by several state AIDS directors to respond to fiscal emergencies affecting ADAPs.